• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.针对突变型p21 ras的T细胞对结肠腺癌细胞系(HT29)的生长抑制作用
Cancer Immunol Immunother. 1994 Feb;38(2):127-34. doi: 10.1007/BF01526208.
2
Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).一名滤泡性甲状腺癌患者的记忆性T细胞识别源自突变型p21 ras(第61位谷氨酰胺突变为亮氨酸)的肽段。
Int Immunol. 1992 Nov;4(11):1331-7. doi: 10.1093/intimm/4.11.1331.
3
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.针对包括突变型ras和嵌合型bcr-abl在内的致癌蛋白的T细胞免疫。
Ann N Y Acad Sci. 1993 Aug 12;690:101-12. doi: 10.1111/j.1749-6632.1993.tb44000.x.
4
CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation.来自一名结肠癌患者的CD8 + T细胞,对一种源自突变型p21-Ras的肽(Gly13→Asp)具有特异性,对携带相同突变的癌细胞系具有细胞毒性。
Cancer Immunol Immunother. 1995 Mar;40(3):165-72. doi: 10.1007/BF01517348.
5
T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.针对癌基因产物的T细胞反应:针对p21 ras衍生合成肽的人T细胞克隆的产生与特性分析
Hum Immunol. 1992 Apr;33(4):266-74. doi: 10.1016/0198-8859(92)90334-j.
6
T-cell recognition of HLA class II molecules induced by gamma-interferon on a colonic adenocarcinoma cell line (HT29).γ-干扰素诱导结肠腺癌细胞系(HT29)上的HLA II类分子的T细胞识别。
Scand J Immunol. 1990 Apr;31(4):469-75. doi: 10.1111/j.1365-3083.1990.tb02794.x.
7
T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction.针对p21 ras衍生肽的T细胞克隆:其精细特异性和HLA限制的特征
Eur J Immunol. 1993 Mar;23(3):754-60. doi: 10.1002/eji.1830230328.
8
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.包含p21 ras第61位突变热点位置的T细胞表位。ras肽与HLA结合的多反应性。
Eur J Immunol. 1994 Feb;24(2):410-4. doi: 10.1002/eji.1830240221.
9
A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.一种人类黑色素瘤细胞系,可被I类和II类HLA限制性T细胞识别,能够引发初次和二次免疫反应。
Scand J Immunol. 1995 Apr;41(4):357-64. doi: 10.1111/j.1365-3083.1995.tb03579.x.
10
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.通过对一名患者进行突变型p21-ras(12Val)肽疫苗接种产生的细胞毒性CD4+和CD8+ T淋巴细胞,识别疫苗肽中存在的12Val依赖性嵌套表位,并杀死携带该突变的自体肿瘤细胞。
Int J Cancer. 1997 Sep 4;72(5):784-90. doi: 10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9.

引用本文的文献

1
Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.在针对一种遗传性癌蛋白的突变区域进行免疫接种后,易患癌小鼠体内原发性肿瘤的生长增强。
J Exp Med. 2000 Jun 5;191(11):1945-56. doi: 10.1084/jem.191.11.1945.
2
K-ras mutations and HLA-DR expression in large bowel adenomas.大肠腺瘤中的K-ras突变与HLA-DR表达
Br J Cancer. 1996 Jul;74(1):99-108. doi: 10.1038/bjc.1996.322.
3
Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody.抗干扰素γ抗体可阻断麦醇溶蛋白敏感T淋巴细胞诱导的小肠黏膜组织学变化。
Gut. 1995 Jun;36(6):874-9. doi: 10.1136/gut.36.6.874.

本文引用的文献

1
Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo.独特型特异性、MHC 限制性 Th1 和 Th2 克隆在体内外的抗肿瘤活性
Scand J Immunol. 1993 Jan;37(1):77-85. doi: 10.1111/j.1365-3083.1993.tb01668.x.
2
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.人癌细胞系白细胞介素-10的产生及其与白细胞介素-6表达的关系。
Int J Cancer. 1993 Aug 19;55(1):96-101. doi: 10.1002/ijc.2910550118.
3
Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis.在大肠癌中,HLA - DR的高表达与良好的预后相关。
Br J Cancer. 1993 Jul;68(1):80-5. doi: 10.1038/bjc.1993.290.
4
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.与HLA - DR等位基因结合的天然加工肽之间的特异性和混杂性。
J Exp Med. 1993 Jul 1;178(1):27-47. doi: 10.1084/jem.178.1.27.
5
The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.独特型特异性CD4 + T细胞在肿瘤抵抗主要组织相容性复合体II类分子阴性浆细胞瘤细胞中的作用。
Cell Immunol. 1993 Apr 15;148(1):177-88. doi: 10.1006/cimm.1993.1100.
6
p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).一名结直肠癌患者的p21-ras肽特异性T细胞反应。CD4+和CD8+ T细胞识别对应于一种常见突变(13甘氨酸→天冬氨酸)的肽段。
Int J Cancer. 1994 Jan 2;56(1):40-5. doi: 10.1002/ijc.2910560108.
7
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.包含p21 ras中一个点突变(12甘氨酸→精氨酸)的重叠表位可被HLA - DR、- DP和 - DQ限制性T细胞识别。
Eur J Immunol. 1993 Oct;23(10):2687-91. doi: 10.1002/eji.1830231045.
8
Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.在Ras蛋白中鉴定出两个细胞毒性T淋巴细胞识别表位。
J Exp Med. 1993 May 1;177(5):1493-8. doi: 10.1084/jem.177.5.1493.
9
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.通过B7转染的黑色素瘤细胞直接共刺激CD8 + T细胞后的肿瘤排斥反应。
Science. 1993 Jan 15;259(5093):368-70. doi: 10.1126/science.7678351.
10
Immunosuppressive factors in human cancer.人类癌症中的免疫抑制因子。
Adv Cancer Res. 1993;60:247-67. doi: 10.1016/s0065-230x(08)60827-1.

针对突变型p21 ras的T细胞对结肠腺癌细胞系(HT29)的生长抑制作用

Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

作者信息

Gedde-Dahl T, Nilsen E, Thorsby E, Gaudernack G

机构信息

Institute of Transplantation Immunology (ITI), National Hospital, Oslo, Norway.

出版信息

Cancer Immunol Immunother. 1994 Feb;38(2):127-34. doi: 10.1007/BF01526208.

DOI:10.1007/BF01526208
PMID:8306368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11038558/
Abstract

Mutations at codons 12, 13 or 61 of the ras proto-oncogenes are found in adenocarcinomas of the colon and rectum. Mutated ras encode tumor-specific proteins, and can elicit CD4+ HLA-class-II-restricted T cell responses both in mouse and man. The function of such T cells is, however, unclear. In a model system, we investigated whether HLA-class-II restricted CD4+ T cells, specific for a particular peptide derived from mutant p21 ras (Gln61-->Leu), might inhibit the growth of a colonic cancer cell line, when it was cultured in the presence of the corresponding peptide. We found in this case that the growth of the colonic adenocarcinoma cell line HT29, when also induced to express HLA class II molecules by interferon gamma treatment, was inhibited. The inhibition was peptide-specific and required the presence of HLA-DQ8 molecules on the target cell. However, HLA-DQ8-expressing HT29 cells functioned poorly as antigen-presenting cells and could only induce a weak proliferative T cell response in the presence of interleukin-2. The results suggest that colonic cancer cells expressing peptides derived from mutant p21 ras protein in a complex with HLA class II molecules may be a target for tumor-specific T cells. The results also indicate, however, that an initiation of the immune response will require "professional" antigen-presenting cells.

摘要

在结肠和直肠腺癌中发现了原癌基因ras密码子12、13或61处的突变。突变的ras编码肿瘤特异性蛋白,并且在小鼠和人类中均可引发CD4⁺ HLA-II类分子限制性T细胞反应。然而,此类T细胞的功能尚不清楚。在一个模型系统中,我们研究了对源自突变型p21 ras(Gln61→Leu)的特定肽具有特异性的HLA-II类分子限制性CD4⁺ T细胞,在相应肽存在的情况下培养时,是否会抑制结肠癌细胞系的生长。在这种情况下,我们发现当通过干扰素γ处理诱导结肠腺癌细胞系HT29也表达HLA-II类分子时,其生长受到抑制。这种抑制是肽特异性的,并且需要靶细胞上存在HLA-DQ8分子。然而,表达HLA-DQ8的HT29细胞作为抗原呈递细胞的功能较差,并且仅在白细胞介素-2存在的情况下才能诱导微弱的T细胞增殖反应。结果表明,与HLA-II类分子形成复合物表达源自突变型p21 ras蛋白的肽的结肠癌细胞可能是肿瘤特异性T细胞的靶标。然而,结果还表明,免疫反应的启动将需要“专业的”抗原呈递细胞。